Navigation Links
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Date:12/6/2008

New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication

PARSIPPANY, N.J., Dec. 6 /PRNewswire/ -- A Phase II dose escalation study of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) in patients who underwent total knee arthroplasty, or TKA, showed that the novel, sustained-release analgesic effectively and safely controlled moderate-to-severe postoperative pain for over 72 hours, it was reported today in a poster at the Biennial World Congress of the International College of Surgeons in Vienna, Austria. Commenting on the results, Kenneth W. Bramlett, MD, Orthopedic Department, West Alabama Research in Birmingham, Alabama concluded EXPAREL significantly reduced postoperative pain, decreased the use of opioids (therefore lowering associated side effects), and allowed some patients to avoid the use of opioids altogether.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

EXPAREL, a proprietary product from Pacira Pharmaceuticals, Inc., is a novel long-acting, sustained-release formulation of bupivacaine HCL, a local anesthetic widely used for treating postoperative pain.

Dr. Bramlett said, "EXPAREL effectively controlled moderate to severe pain for more than 72 hours, with better relief achieved with higher doses and a dose-dependent effect in both analgesia and reduction in opioid rescue." He pointed out the clinical importance of the study outcomes noting that EXPAREL efficacy was statistically significant against bupivacaine, the gold standard of local anesthetics, rather than simply placebo, concluding, "EXPAREL may provide safe and effective, prolonged pain relief and an opioid-sparing alternative to currently available local analgesics."


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
2. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
3. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical ... on women,s healthcare and pain management, announced today ... The round was led by Longitude Capital ... Point Capital. Other current investors that participated in ...
... Center Association, JWCH Institute and the County of Los ... Community Health Downtown Los Angeles, a state-of-the-art medical facility ... homeless and low-income people in and around Skid Row. ... Street, is expected to meet the healthcare needs of ...
Cached Medicine Technology:Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
... Microvolume technology , The ADVIA 1650 has ... as 2 L/test), reagent consumption (as low ... L/hour) - thus maximizing management efficiency. , ... cycle and system throughput of up to ...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
Medicine Products: